JAMA · 2020
Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement.
СтатьяКлинические рекомендацииПоддержка службы здравоохранения СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
US Preventive Services Task Force, Owens Douglas K, Davidson Karina W, Krist Alex H, Barry Michael J, Cabana Michael, Caughey Aaron B, Donahue Katrina, Doubeni Chyke A, Epling John W, Kubik Martha, Ogedegbe Gbenga, Pbert Lori, Silverstein Michael, Simon Melissa A, Tseng Chien-Wen, Wong John B
Аннотация
IMPORTANCE: Hepatitis C virus (HCV) is the most common chronic blood-borne pathogen in the US and a leading cause of complications from chronic liver disease. HCV is associated with more deaths than the top 60 other reportable infectious diseases combined, including HIV. Cases of acute HCV infection have increased approximately 3.8-fold over the last decade because of increasing injection drug use and improved surveillance.
OBJECTIVE: To update its 2013 recommendation, the USPSTF commissioned a review of the evidence on screening for HCV infection in adolescents and adults.
POPULATION: This recommendation applies to all asymptomatic adults aged 18 to 79 years without known liver disease.
EVIDENCE ASSESSMENT: The USPSTF concludes with moderate certainty that screening for HCV infection in adults aged 18 to 79 years has substantial net benefit.
RECOMMENDATION: The USPSTF recommends screening for HCV infection in adults aged 18 to 79 years. (B recommendation).
OBJECTIVE: To update its 2013 recommendation, the USPSTF commissioned a review of the evidence on screening for HCV infection in adolescents and adults.
POPULATION: This recommendation applies to all asymptomatic adults aged 18 to 79 years without known liver disease.
EVIDENCE ASSESSMENT: The USPSTF concludes with moderate certainty that screening for HCV infection in adults aged 18 to 79 years has substantial net benefit.
RECOMMENDATION: The USPSTF recommends screening for HCV infection in adults aged 18 to 79 years. (B recommendation).